...
首页> 外文期刊>Current pharmaceutical design >In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models
【24h】

In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models

机译:药物吸入气雾剂递送中的体外肺细胞培养:2-D,3-D和原位生物影响器模型

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The use of non-invasive inhaled aerosols for pulmonary drug delivery continues to grow. This is due to the many unique advantages this delivery route offers for the treatment of both local and systemic diseases. The physicochemical properties of the formulated drugs as well as the physiology of the lungs play a key role in both the deposition and absorption of the particles. The airway and the alveolar epithelium are targets for the treatment of respiratory diseases. However, particles have to overcome biological barriers before they reach their target and produce an effect. Methods: In vitro aerosol dispersion performance (i.e. aerodynamic size and aerodynamic size distribution) of inhalable particles is quantified by inertial impaction, as required by regulatory agencies for an investigational pharmaceutical inhalation aerosol formulation to be approved for use in patients as a marketed pharmaceutical product. Using inertial impaction in conjunction with cell cultures of various pulmonary cells in situ as bioimpactors has unique aspects in correlating aerodynamic properties with pulmonary cellular behavior including viability and uptake. These can be as co-culture or in single culture, as 3-D multicellular spheroids or 2-D cellular monolayer using different conditions to grow them, such as air-liquid interface culture (ALI) or in liquid covered culture (LCC). Results: evaluation of the currently available in vitro models and the challenges in developing reliable cellular tools to predict the deposition of inhalable particles in the lungs as a function of aerodynamic particle properties is presented in the manuscript. Conclusion: The mechanistic aerodynamic and biophysical properties of inhaled aerosol particles on the entire respiratory tract at the cellular level based on aerodynamic size and aerodynamic size distribution will be better understood with the development of in vitro methods which are described in this work.
机译:背景:无创吸入气雾剂用于肺部药物递送的使用持续增长。这是由于该递送途径为局部和全身性疾病的治疗提供了许多独特的优势。配制药物的物理化学性质以及肺部的生理在颗粒的沉积和吸收中都起着关键作用。气道和肺泡上皮是治疗呼吸系统疾病的目标。但是,粒子必须在达到目标并产生效果之前克服生物障碍。方法:根据监管机构要求,经研究批准的可吸入药物气雾剂制剂的可吸入颗粒的体外气溶胶分散性能(即,空气动力学尺寸和空气动力学尺寸分布)通过惯性撞击进行定量,以允许其作为市售药品用于患者。将惯性撞击与各种肺细胞原位细胞培养物结合使用作为生物干扰物,在将空气动力学特性与肺细胞行为(包括生存力和摄取)相关联方面具有独特之处。这些可以是共培养或单培养,也可以是3-D多细胞球体或2-D细胞单层,使用不同的条件使其生长,例如气液界面培养(ALI)或液体覆盖培养(LCC)。结果:手稿中介绍了当前可用的体外模型的评估以及开发可靠的细胞工具以预测可吸入颗粒在肺中的沉积情况(取决于空气动力学颗粒特性)的挑战。结论:根据这项工作中描述的体外方法的发展,可以更好地了解基于空气动力学尺寸和空气动力学尺寸分布在细胞水平上整个呼吸道吸入气溶胶颗粒的机械空气动力学和生物物理特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号